**NEWS RELEASE**

**For Further Information Contact:**
Erik Danielsen
Nymox Pharmaceutical Corporation
1-800-93NYMOX
www.nymox.com

**For Immediate Release:**

# NYMOX Successfully Achieves Manufacturing Scale-Up

HASBROUCK HEIGHTS, NJ (June 7, 2018) Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to report that manufacturing scale-up milestones have been reached for the Company's lead compound Fexapotide Triflutate (FT). Over the past year, the Company has worked intensively for its lead-drug scale-up of the manufacturing batches in anticipation of regulatory filings and clearances of FT for the millions of men suffering from prostate enlargement (BPH). The Company has now successfully and significantly increased the batch size and yield for the sterile injectable drug. As a result of the successful scale-up, the Company has also significantly augmented its inventory of fully validated drug and potentially marketable inventory. The recently achieved scale-up (by a factor of >10X) allows for realistic expansion of marketing plans for FT in major world markets. Marketing requires approvals from regulatory authorities, which has not yet been granted.

The scaled up sterile injectable FT (finished product) is manufactured as a lyophilized powder which has excellent shelf life when stored at room temperature, frozen or refrigerated.

"We are very excited by the achievement of these key results, and we anticipate that these new manufacturing milestones will allow for wider marketing plans to now become considerably more practically feasible", said Dr. Paul Averback, CEO of Nymox.

Dr. Suresh Kalbag, Nymox head of chemistry and manufacturing operations, stated: “To successfully achieve manufacturing scale-up, is no trivial task for any pharmaceutical product. The process is inherently associated with unknown risks and challenges. We are therefore extremely pleased with the team’s achievement and accomplishment over this past year and that we were able to successfully execute this critical project on time and within budget”.

Nymox also announced today an additional $2,000,000.00 in funding from a long-term shareholder. The funding was done at $3.00 per share and there were no fees incurred in the transaction. The additional funding brings the recent net funding total to 18.25 million USD. Treasury funding of 16.25 million USD from qualified long-term investors was announced recently on April 12, 2018.

Nymox's lead drug Fexapotide has been in development for over 10 years and has been tested by expert clinical trial investigative teams in over 70 distinguished clinical trial centers throughout the US, and has been found after 7 years of prospective placebo controlled double blind studies of treatment of 995 U.S. men with prostate enlargement to not only show clinically meaningful and durable relief of BPH symptoms, but also to show a major reduction in the incidence of prostate cancer, compared to placebo and compared to the known and expected normal incidence of the disease. The same clinical program has also shown in a long-term blinded placebo group study an 82-95% reduction in the number of these patients who required surgery after they received Fexapotide in the trial, as compared to patients who did not receive Fexapotide but instead later received conventional approved BPH treatments (p<.0001).

For more information please contact info@nymox.com or 800-936-9669.

Forward Looking Statements

To the extent that statements contained in this press release are not descriptions of historical facts regarding Nymox, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the need for new options to treat BPH and prostate cancer, the potential of Fexapotide to treat BPH and prostate cancer and the estimated timing of further developments for Fexapotide. Such forward-looking statements involve substantial risks and uncertainties that could cause our clinical development program, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the clinical drug development process, including the regulatory approval process, the timing of Nymox's regulatory filings, Nymox's substantial dependence on Fexapotide, Nymox's commercialization plans and efforts and other matters that could affect the availability or commercial potential of Fexapotide. Nymox undertakes no obligation to update or revise any forward looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Nymox in general, see Nymox's current and future reports filed with the U.S. Securities and Exchange Commission, including its Annual Report on Form 20-F for the year ended December 31, 2017, and its Quarterly Reports.